{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:55:50Z","timestamp":1794642950552,"version":"4.9.1"},"reference-count":43,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,7,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Adolescents and young adults (AYAs) comprise the largest age group affected by Hodgkin lymphoma (HL). Despite excellent overall survival of AYA patients with HL due to advances in treatment regimens, therapy-associated late effects continue to be a concern in HL survivors, especially for younger patients who have decades of life remaining. Since the first clinical trial for HL with chemotherapy in 1964, subsequent protocols have attempted to reduce chemotherapy-induced toxicities and yet maintain high overall survival rates. Today, new analytic methods applied to data from survivorship cohorts, such as the recently described cumulative burden of disease metric, can be used to inform changes for future protocols. Although pediatric and adult trial consortia have followed this process, the AYA population, an age cohort split between pediatric and adult health care services, faces many barriers to care and is the least likely to be enrolled in clinical trials. AYA patients with HL theoretically have a choice to be treated in pediatric or adult protocols when presented with these options. Recent efforts by the National Clinical Trials Network, the Children\u2019s Oncology Group, and others have been made to ensure that the burden of choice for the AYA population is not greater than the burden of disease.<\/jats:p>","DOI":"10.1182\/blood-2018-01-778548","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T14:05:36Z","timestamp":1528812336000},"page":"376-384","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["The management of Hodgkin lymphoma in adolescents and young adults: burden of disease or burden of choice?"],"prefix":"10.1182","volume":"132","author":[{"given":"Jamie E.","family":"Flerlage","sequence":"first","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"The University of Tennessee Health Sciences Center, Memphis, TN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika L.","family":"Metzger","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"The University of Tennessee Health Sciences Center, Memphis, TN; and"},{"name":"Department of Global Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickhill","family":"Bhakta","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN;"},{"name":"The University of Tennessee Health Sciences Center, Memphis, TN; and"},{"name":"Department of Global Pediatric Medicine, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111818491993100_B1","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program, Surveillance Research Program, Division of Cancer Control and Population Sciences (DCCPS), National Cancer Institute. Program research data (1973-2014), released December 2017. www.seer.cancer.gov. Accessed 5 December 2017."},{"issue":"6","key":"2019111818491993100_B2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2010-04-278796","article-title":"Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study","volume":"117","author":"Castellino","year":"2011","journal-title":"Blood"},{"issue":"18","key":"2019111818491993100_B3","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1200\/JCO.2002.20.18.3755","article-title":"Pediatric Hodgkin\u2019s therapy: time for a paradigm shift","volume":"20","author":"Hudson","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019111818491993100_B4","first-page":"O_09","article-title":"Intensive therapy free survival (ITFS) for early-stage Hodgkin Lymphoma (cHL) including chemotherapy and radiation therapy (IFRT) for recurrence after chemotherapy alone","volume-title":"Klin Padiatr","author":"Keller","year":"2014"},{"issue":"25","key":"2019111818491993100_B5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"9933","key":"2019111818491993100_B6","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0140-6736(14)60114-8","article-title":"Childhood cancer, endocrine disorders, and cohort studies","volume":"383","author":"Oeffinger","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"2019111818491993100_B7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1634\/theoncologist.11-6-590","article-title":"Cancer in 15- to 29-year-olds by primary site","volume":"11","author":"Bleyer","year":"2006","journal-title":"Oncologist"},{"issue":"suppl 7","key":"2019111818491993100_B8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/cncr.22102","article-title":"Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials","volume":"107","author":"Bleyer","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2019111818491993100_B9","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1158\/1055-9965.EPI-15-0281","article-title":"Time trends in rates of Hodgkin lymphoma histologic subtypes: true incidence changes or evolving diagnostic practice?","volume":"24","author":"Glaser","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"2019111818491993100_B10","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.29869","article-title":"Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults","volume":"122","author":"Keegan","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"2019111818491993100_B11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ctrv.2006.11.005","article-title":"Participation of adolescents with cancer in clinical trials","volume":"33","author":"Ferrari","year":"2007","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2019111818491993100_B12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/1042819042000209404","article-title":"Long term outcome in adolescents with Hodgkin\u2019s lymphoma: poor results using regimens designed for adults","volume":"45","author":"Yung","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"2019111818491993100_B13","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2005.04.5823","article-title":"Hodgkin\u2019s lymphoma in adolescents","volume":"24","author":"Foltz","year":"2006","journal-title":"J Clin Oncol"},{"issue":"36","key":"2019111818491993100_B14","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1200\/JCO.2008.20.2655","article-title":"Hodgkin\u2019s lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin Study Group","volume":"27","author":"Eichenauer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111818491993100_B15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.30979","article-title":"Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: an adult intergroup (E2496) and Children\u2019s Oncology Group (COG AHOD0031) comparative analysis","volume":"124","author":"Henderson","year":"2018","journal-title":"Cancer"},{"issue":"11","key":"2019111818491993100_B16","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.1998.16.11.3592","article-title":"Increased mortality after successful treatment for Hodgkin\u2019s disease","volume":"16","author":"Hudson","year":"1998","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111818491993100_B17","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2014.59.4853","article-title":"Pediatric Hodgkin lymphoma","volume":"33","author":"Mauz-K\u00f6rholz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111818491993100_B18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1055\/s-2004-822627","article-title":"The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin\u2019s disease: evolution in the tradition of the DAL\/GPOH studies","volume":"216","author":"K\u00f6rholz","year":"2004","journal-title":"Klin Padiatr"},{"key":"2019111818491993100_B19","unstructured":"ClinicalTrials.gov. Second international inter-group study for classical Hodgkin lymphoma in children and adolescents. Identifier NCT02684708. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02684708?recrs=a&cond=Hodgkin&age=0&rank=6. Accessed 1 December 2017."},{"issue":"10","key":"2019111818491993100_B20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"key":"2019111818491993100_B21","unstructured":"ClinicalTrials.gov. Brentuximab vedotin and combination chemotherapy in treating children and young adults with stage IIB or stage IIIB-IVB Hodgkin lymphoma. Identifier NCT02166463. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02166463?recrs=a&cond=Hodgkin&age=0&draw=2&rank=10.Accessed 1 December 2017."},{"issue":"24","key":"2019111818491993100_B22","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1001\/jama.2012.5847","article-title":"Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma","volume":"307","author":"Metzger","year":"2012","journal-title":"JAMA"},{"issue":"3","key":"2019111818491993100_B23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2006.08.4772","article-title":"Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin\u2019s disease","volume":"25","author":"Donaldson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111818491993100_B24","unstructured":"ClinicalTrials.gov. Adcetris (brentuximab vedotin), combination chemotherapy, and radiation therapy in treating younger patients with stage IIB, IIIB and IV Hodgkin lymphoma. Identifier NCT01920932. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920932?recrs=a&cond=Hodgkin+Lymphoma&age=0&rank=9. Accessed 1 December 2017."},{"key":"2019111818491993100_B25","unstructured":"ClinicalTrials.gov. Brentuximab vedotin combined with AVD chemotherapy in patients with newly diagnosed early stage, unfavorable risk Hodgkin lymphoma. Identifier NCT01868451. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01868451?id=NCT02979522+OR+NCT03033914+OR+NCT02398240+OR+NCT03004833+OR+NCT03331341+OR+NCT01868451+OR+NCT02684708+OR+NCT01920932+OR+NCT02298283+OR+NCT02661503+OR+NCT03226249+OR+NCT03233347+OR+NCT02166463&rank=13&load=cart. Accessed 1 December 2017."},{"issue":"4","key":"2019111818491993100_B26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"2019111818491993100_B27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fonc.2014.00317","article-title":"The impact of protocol assignment for older adolescents with Hodgkin lymphoma","volume":"4","author":"Pieters","year":"2014","journal-title":"Front Oncol"},{"issue":"3","key":"2019111818491993100_B28","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/pbc.23385","article-title":"Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies","volume":"58","author":"Hudson","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"2019111818491993100_B29","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJMoa1510795","article-title":"Reduction in late mortality among 5-year survivors of childhood cancer","volume":"374","author":"Armstrong","year":"2016","journal-title":"N Engl J Med"},{"issue":"10112","key":"2019111818491993100_B30","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0140-6736(17)31610-0","article-title":"The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)","volume":"390","author":"Bhakta","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"2019111818491993100_B31","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111818491993100_B32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/aje\/kwu289","article-title":"Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count","volume":"181","author":"Dong","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"22","key":"2019111818491993100_B33","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1001\/jama.2013.6296","article-title":"Clinical ascertainment of health outcomes among adults treated for childhood cancer","volume":"309","author":"Hudson","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"2019111818491993100_B34","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(09)70258-X","article-title":"Quality of life after successful treatment of early-stage Hodgkin\u2019s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial","volume":"10","author":"Heutte","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"2019111818491993100_B35","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00520-013-2114-y","article-title":"Quality of life in long-term survivors following treatment for Hodgkin\u2019s disease during childhood and adolescence in the German multicentre studies between 1978 and 2002","volume":"22","author":"Calaminus","year":"2014","journal-title":"Support Care Cancer"},{"issue":"suppl 15","key":"2019111818491993100_B36","article-title":"Relationship between the cumulative burden (CB) of chronic health conditions (CHC) and health-related quality of life (HRQoL) among childhood cancer survivors (CCS): the St. Jude Lifetime (SJLIFE) cohort [abstract]","volume":"35","author":"Bhakta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111818491993100_B37","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1053\/j.seminoncol.2015.07.012","article-title":"Enhancing adolescent and young adult oncology research within the National Clinical Trials Network: rationale, progress, and emerging strategies","volume":"42","author":"Weiss","year":"2015","journal-title":"Semin Oncol"},{"issue":"3","key":"2019111818491993100_B38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/jayao.2014.0041","article-title":"Who treats adolescents and young adults with cancer? A report from the AYA HOPE Study","volume":"4","author":"Parsons","year":"2015","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2019111818491993100_B39","unstructured":"ClinicalTrials.gov. Therapy for pediatric Hodgkin lymphoma. Identifier NCT00145600. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00145600?term=HOD99&rank=2. Accessed 1 December 2017."},{"key":"2019111818491993100_B40","unstructured":"ClinicalTrials.gov. Brentuximab for newly diagnosed Hodgkin disease. Identifier NCT02398240. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02398240?term=NYMC+568&rank=1. Accessed 1 December 2017."},{"key":"2019111818491993100_B41","unstructured":"ClinicalTrials.gov. HD21 for advanced stages. Identifier NCT02661503. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02661503?id=NCT02979522+OR+NCT03033914+OR+NCT02398240+OR+NCT03004833+OR+NCT03331341+OR+NCT01868451+OR+NCT02684708+OR+NCT01920932+OR+NCT02298283+OR+NCT02661503+OR+NCT03226249+OR+NCT03233347+OR+NCT02166463&rank=8&load=cart. Accessed 1 December 2017."},{"key":"2019111818491993100_B42","unstructured":"ClinicalTrials.gov. Comparison of two combination chemotherapy regimens in treating patients with stage III or stage IV Hodgkin\u2019s lymphoma. Identifier NCT00049595. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00049595?term=EORTC&cond=Hodgkin&rank=6. Accessed 1 December 2017."},{"key":"2019111818491993100_B43","unstructured":"ClinicalTrials.gov. A(B)VD followed by nivolumab as frontline therapy for higher risk patients with classical Hodgkin lymphoma. Identifier NCT03033914. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03033914?id=NCT02979522+OR+NCT03033914+OR+NCT02398240+OR+NCT03004833+OR+NCT03331341+OR+NCT01868451+OR+NCT02684708+OR+NCT01920932+OR+NCT02298283+OR+NCT02661503+OR+NCT03226249+OR+NCT03233347+OR+NCT02166463&rank=4&load=cart. Accessed 1 December 2017."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/4\/376\/1407448\/blood778548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/132\/4\/376\/1407448\/blood778548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T18:49:38Z","timestamp":1574102978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/132\/4\/376\/103907\/The-management-of-Hodgkin-lymphoma-in-adolescents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-01-778548","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]}}}